Press Release



Sensorion Announces Its Participation in Upcoming
Investor Conferences to be Held in November 2024

Montpellier, November 6, 2024, 7.30 am CET – Sensorion (FR0012596468 – ALSEN) a pioneering
clinical-stage biotechnology company which specializes in the development of novel therapies to
restore, treat and prevent within the field of hearing loss disorders, today announced its participation in
upcoming investor conferences to take place in November 2024.

• Sensorion will participate in the Stifel Healthcare Conference, which will be held in New York,
USA, on November 18-19, 2024. Sensorion's management team will be present for one-to-one
meetings on November 18, 2024.

• Sensorion will also participate in the LifeSci Capital and Sofinnova Partners Growth &
Innovation Summit, to take place in London, UK, on November 18, 2024. Sensorion's
management team will be present for one-to-one meetings throughout the conference.

• Sensorion will also be attending the Jefferies London Healthcare Conference, in London, UK,
on November 19-21, 2024. Sensorion's management team will be present for one-to-one
meetings throughout the conference.

If you would like to meet Sensorion's management team, please contact us by email:
ir.contact@sensorion-pharma.com



About Sensorion
Sensorion is a pioneering clinical-stage biotech company, which specializes in the development of novel therapies
to restore, treat, and prevent hearing loss disorders, a significant global unmet medical need. Sensorion has built a
unique R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear
related diseases, enabling it to select the best targets and mechanisms of action for drug candidates.
It has two gene therapy programs aimed at correcting hereditary monogenic forms of deafness, developed in the
framework of its broad strategic collaboration focused on the genetics of hearing with the Institut Pasteur. SENS-
501 (OTOF-GT) currently being developed in a Phase 1/2 clinical trial, targets deafness caused by mutations of the
gene encoding for otoferlin and GJB2-GT targets hearing loss related to mutations in GJB2 gene to potentially
address important hearing loss segments in adults and children. The Company is also working on the identification
of biomarkers to improve diagnosis of these underserved illnesses.
Sensorion’s portfolio also comprises clinical-stage small molecule programs for the treatment and prevention of
hearing loss disorders. Sensorion’s clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron)
progressing in a planned Phase 2 proof of concept clinical study of SENS-401 in Cisplatin-Induced Ototoxicity (CIO)
and, with partner Cochlear Limited, has completed in a study of SENS-401 in patients scheduled for cochlear
implantation. A Phase 2 study of SENS-401 was also completed in Sudden Sensorineural Hearing Loss (SSNHL)
in January 2022.
www.sensorion.com



Contacts
Investor Relations Press Relations
Noémie Djokovic, Investor Relations and Ulysse Communication
Communication Associate Bruno Arabian / 00 33(0)6 87 88 47 26
ir.contact@sensorion-pharma.com barabian@ulysse-communication.com
Nicolas Entz / 00 33 (0)6 33 67 31 54
nentz@ulysse-communication.com
Press Release


Label: SENSORION
ISIN: FR0012596468
Mnemonic: ALSEN



Disclaimer
This press release contains certain forward-looking statements concerning Sensorion and its business. Such
forward looking statements are based on assumptions that Sensorion considers to be reasonable. However, there
can be no assurance that such forward-looking statements will be verified, which statements are subject to
numerous risks, including the risks set forth in the 2023 full year report published on March 14, 2024, and available
on our website and to the development of economic conditions, financial markets and the markets in which
Sensorion operates. The forward-looking statements contained in this press release are also subject to risks not
yet known to Sensorion or not currently considered material by Sensorion. The occurrence of all or part of such
risks could cause actual results, financial conditions, performance or achievements of Sensorion to be materially
different from such forward-looking statements. This press release and the information that it contains do not
constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Sensorion shares
in any country. The communication of this press release in certain countries may constitute a violation of local laws
and regulations. Any recipient of this press release must inform oneself of any such local restrictions and comply
therewith.